TCGA-A7-A0DB-01A-11R-A277-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 34
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.370
- PROTEIN_SECRETION+0.300
- ANDROGEN_RESPONSE+0.200
- KRAS_SIGNALING_UP+0.180
- BILE_ACID_METABOLISM+0.170
- MITOTIC_SPINDLE+0.170
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.090
- SPERMATOGENESIS+0.080
- FATTY_ACID_METABOLISM+0.070
- TGF_BETA_SIGNALING+0.070
Top 10 suppressed
- MYC_TARGETS_V2-0.580
- DNA_REPAIR-0.430
- INTERFERON_ALPHA_RESPONSE-0.410
- MYC_TARGETS_V1-0.400
- UV_RESPONSE_UP-0.370
- E2F_TARGETS-0.360
- TNFA_SIGNALING_VIA_NFKB-0.360
- INTERFERON_GAMMA_RESPONSE-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- PANCREAS_BETA_CELLS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030399_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.885 |
| 2 | TCGA-A7-A13G-01A-11R-A13Q-07 | — | D | 0.854 |
| 3 | TCGA-A7-A26E-01A-11R-A169-07 | — | B | 0.841 |
| 4 | TCGA-A7-A0DB-01C-02R-A277-07 | — | D | 0.840 |
| 5 | TCGA-BL-A0C8-01B-04R-A277-07 | — | — | 0.821 |
| 6 | SRR655555 | GTEX | — | 0.820 |
| 7 | TCGA-A7-A26E-01A-11R-A277-07 | — | D | 0.809 |
| 8 | ERR2598056 | fetal | fetal | 0.806 |
| 9 | MDT-AP-3025 | Med | Medulloblastoma | 0.803 |
| 10 | TCGA-44-6147-01A-11R-A278-07 | — | cohortMD2 | 0.803 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.370 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.090 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.030 | Remibrutinib | — uncovered |